British american tobacco plc(BTI.US AI Earnings Summary)
BTI AI Earnings Summary (In-Depth)
2025 Q4
Key Highlights
- Stock Price Reaction: Results were released at 7:00 a.m. London time on February 12, 2026, before the U.S. open; on that first trading day after earnings, the ADR closed at $60.61, up 0.46% from the February 11 close of $60.33.
- Market Expectations: FY2025 revenue grew 2.1% YoY, adjusted operating profit grew 2.3% YoY, and adjusted diluted EPS grew 3.4% YoY; financial results reached the upper end of previous expectations.
- Guidance Achievement: Successfully delivered on all FY2025 priorities, with financial results at the top end of the company's original constant-currency guidance range, demonstrating strong execution.
- In a Nutshell: Despite strong progress in the smokeless product transformation and earnings reaching the upper end of expectations in FY2025, management estimates FY2026 performance will fall at the lower end of medium-to-long-term growth targets. The market viewed this cautiously, responding with a 1.83% decline on closing day.
Quarterly Highlights
U.S. Business Returns to Growth: 2025 U.S. revenue grew 4.6% YoY and adjusted profit grew 5.9% YoY, marking the first full-year positive growth since 2022. The combustibles business contributed 1% to revenue growth and gained 30 basis points of value market share.
Global Leadership in Modern Oral Products: Velo Plus achieved 300% growth in its first year of launch, capturing 80% of industry value growth in December. Global modern oral market share reached leadership positions in key markets, with Velo's scale in Europe being 6 times that of its nearest competitor.
New Category Contribution Increases Significantly: New Category contribution grew 77% YoY to £442M, with gross profit increasing by over £200M. The category contribution has improved by a cumulative £1.4B since 2021, demonstrating economies of scale and investment discipline.
Full-Year Performance Better Than Expected: Group revenue grew 2.1% YoY, adjusted operating profit grew 2.3% YoY, and adjusted diluted EPS grew 3.4% YoY, all reaching the upper end of full-year guidance, with visible acceleration in momentum during the second half.
Cash Returns Continue to Strengthen: 2026 dividend increased 2% YoY; share buyback amount was raised by £200M to £1.3B. Adjusted net debt to EBITDA decreased to 2.55x, and the cumulative free cash flow target of over £50B by 2030 remains maintained.
Productivity Program Accelerates: Cumulative cost savings of £1.2B realized since 2023. The Fit2Win program was revised upward to contribute £600M in annual savings by 2028, with a target of saving an additional £2B by 2030.
U.S. Regulatory Environment Turns Positive: Vuse returned to revenue growth in the second half; state-level enforcement covers 50% of the legal market. The FDA initiated streamlined PMTA reviews for nicotine pouches, and an ITC preliminary ruling favored the exclusion of illicit products.